Jeffrey S. Parkin

Array ( [id] => 10797862 [patent_doc_number] => 20160144019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'Novel Therapeutic and Diagnostic Means' [patent_app_type] => utility [patent_app_number] => 14/952292 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20037 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641244 [patent_doc_number] => 20180105579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/527511 [patent_app_country] => US [patent_app_date] => 2015-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10805321 [patent_doc_number] => 20160151478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'Novel Flavivirus Antigens' [patent_app_type] => utility [patent_app_number] => 14/942079 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 139867 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14942079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11628767 [patent_doc_number] => 20170138956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'METHODS OF DETERMINING SEROTYPE SPECIFICITY OF AN ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/316077 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9578 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15316077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300945 [patent_doc_number] => 20180202009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => HIV PATHOLOGY MARKER AND EXAMINATION METHOD [patent_app_type] => utility [patent_app_number] => 15/523276 [patent_app_country] => US [patent_app_date] => 2015-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15523276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058630 [patent_doc_number] => 20170334973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS' [patent_app_type] => utility [patent_app_number] => 15/522357 [patent_app_country] => US [patent_app_date] => 2015-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 30874 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15522357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10695022 [patent_doc_number] => 20160041168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 14/921746 [patent_app_country] => US [patent_app_date] => 2015-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 13991 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14921746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11009751 [patent_doc_number] => 20160206705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'ANTIVIRAL ACTIVITY OF GAS6 INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/918442 [patent_app_country] => US [patent_app_date] => 2015-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15286 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13565893 [patent_doc_number] => 20180334494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => RECOMBINANT ANTIBODIES THAT RECONGNIZE THE C-TERMINAL DOMAINS OF EBOLA VIRUS NUCLEOPROTEIN [patent_app_type] => utility [patent_app_number] => 15/518417 [patent_app_country] => US [patent_app_date] => 2015-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559810 [patent_doc_number] => 11725044 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity [patent_app_type] => utility [patent_app_number] => 15/516742 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12606 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000208 [patent_doc_number] => 20170304363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING VIRAL HEMORRHAGIC FEVER' [patent_app_type] => utility [patent_app_number] => 15/517133 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24033 [patent_no_of_claims] => 121 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12029581 [patent_doc_number] => 20170319679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'HIV Vaccines Comprising One or More Population Episensus Antigens' [patent_app_type] => utility [patent_app_number] => 15/516491 [patent_app_country] => US [patent_app_date] => 2015-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 22017 [patent_no_of_claims] => 156 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942058 [patent_doc_number] => 20170246209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'TREATING VIRAL HEMORRHAGIC FEVER WITH NK-92 CELLS' [patent_app_type] => utility [patent_app_number] => 15/517011 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7682 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10728353 [patent_doc_number] => 20160074502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE' [patent_app_type] => utility [patent_app_number] => 14/861425 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16673 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14861425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000271 [patent_doc_number] => 20170304427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE' [patent_app_type] => utility [patent_app_number] => 15/508851 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 32501 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10694041 [patent_doc_number] => 20160040188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus' [patent_app_type] => utility [patent_app_number] => 14/833913 [patent_app_country] => US [patent_app_date] => 2015-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 17223 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14833913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512787 [patent_doc_number] => 10562969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Substitution monotherapy treatment for HIV-1 infection employing antibody PRO140 [patent_app_type] => utility [patent_app_number] => 15/504928 [patent_app_country] => US [patent_app_date] => 2015-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15821 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15504928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979332 [patent_doc_number] => 20170283486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'STABLE IMMUNOGEN BASED ON INNER DOMAIN OF HIV-1 GP120 FOR INDUCING IMMUNITY AGAINST HIV' [patent_app_type] => utility [patent_app_number] => 15/504770 [patent_app_country] => US [patent_app_date] => 2015-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 18768 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15504770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969909 [patent_doc_number] => 20170274063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'THERMOSTABLE, CHROMATOGRAPHICALLY PURIFIED NANO-VLP VACCINE' [patent_app_type] => utility [patent_app_number] => 15/508719 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20760 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11075721 [patent_doc_number] => 20160272685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'APPROACH TO PRODUCE HIV-1 GP140 ENVELOPE PROTEIN TRIMERS' [patent_app_type] => utility [patent_app_number] => 14/806735 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 32927 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14806735 [rel_patent_id] =>[rel_patent_doc_number] =>)